• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Relay Therapeutics Inc (NQ: RLAY )

    6.105 -0.145 (-2.32%)
    Streaming Delayed Price Updated: 1:05 PM EST, Nov 7, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Relay Therapeutics Inc

    < Previous 1 2 3 4 5 6 7 Next >
    Expert Ratings For Relay Therapeutics
    Via Benzinga
    Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
    The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
    Via Talk Markets
    Clinical-Stage BioTech Drug Stocks Declined 13% In June
    Our BioTech Drug Stocks Portfolio was DOWN 13.2% in June. Before proceeding read 
    Via Talk Markets
    Largest Clinical-Stage BioTech Drug Stocks Declined 6%
    Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they... 
    Via Talk Markets
    AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th
    The global 
    Via Talk Markets
    Expert Ratings For Relay Therapeutics
    Via Benzinga
    Key Takeaways From Relay Therapeutics Analyst Ratings
    Via Benzinga
    Relay Therapeutics: Q4 Earnings Insights
    Via Benzinga
    Relay Therapeutics's Earnings: A Preview
    Via Benzinga
    AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week
    The global 
    Via Talk Markets
    Relay Therapeutics Discloses Three New Programs at New Program & Platform Event
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
    Initial triplet combination of RLY-2608 + atirmociclib + fulvestrant to be evaluated in patients with PI3Kα-mutated HR+/HER2- metastatic breast cancer; initiation planned by end of 2024 
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
    This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our... 
    Via Talk Markets
    Relay Therapeutics to Participate in Upcoming Investor Conferences
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    Relay Therapeutics to Host New Program and Platform Event on June 6, 2024
    Company to disclose new programs from existing unnamed pre-clinical pipeline 
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    5 Of 7 AI Categories Rose, Slightly,Over Past Week
    The 7 AI categories we track went up marginally (1.0%, on average) the second week of May, after having gone down 0.4% the previous week. 
    Via Talk Markets
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    The 7 AI Categories Declined, On Average, The First Week Of May
    Via Talk Markets
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
    We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD. 
    Via Talk Markets
    RLAY Stock Earnings: Relay Therapeutics Beats EPS, Beats Revenue for Q1 2024
    RLAY stock results show that Relay Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
    Approximately $750 million in cash, cash equivalents and investments at end of Q1 2024, expected to fund operations into second half of 2026 
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
    A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and... 
    Via Talk Markets
    Relay Therapeutics to Participate in Upcoming Investor Conferences
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    AI Surge Ending: Only One Category Was Up This Week
    Six of the 7 categories we cover dropped this week, compared with 3 in March. The data clearly indicates that the surge in this sector is stalling or perhaps is even over. 
    Via Talk Markets
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    3 Precision Medicine Stocks That Could Benefit From the Industry’s Rise
    Dive into the potential of precision medicine stocks poised to revolutionize healthcare and offer substantial growth opportunities. 
    Via InvestorPlace
    AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
    Grand View Research says the global 
    Via Talk Markets
    Relay Therapeutics to Participate in Three Upcoming Investor Conferences
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    Earnings Scheduled For February 22, 2024
    Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.